Avoro Capital Advisors LLC Increases Stake in Soleno Therapeutics Inc
Avoro Capital Advisors LLC has increased its stake in Soleno Therapeutics Inc. by purchasing an additional 322,223 shares at $46.3 per share, bringing its total holdings to 2.9 million shares. This move underscores Avoro's confidence in Soleno's biopharmaceutical focus on rare diseases, despite the latter's recent stock decline and low profitability and growth ranks. The transaction highlights continued investor interest in Soleno, with other notable investors including Vanguard Health Care Fund.
CenterBook Partners LP Acquires 38,282 Shares of Soleno Therapeutics, Inc. $SLNO
CenterBook Partners LP increased its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 156.2% in the third quarter, acquiring an additional 38,282 shares. Other institutional investors like Vanguard Group Inc., Westfield Capital Management Co. LP, State Street Corp, Geode Capital Management LLC, and Emerald Advisers LLC also significantly boosted their holdings. The stock currently has an average rating of "Moderate Buy" with an average target price of $110.62 from analysts.
Skandinaviska Enskilda Banken AB publ Increases Stock Holdings in Soleno Therapeutics, Inc. $SLNO
Skandinaviska Enskilda Banken AB publ significantly increased its stake in Soleno Therapeutics, Inc. by 320.3% in the third quarter, acquiring an additional 93,536 shares to hold a total of 122,739 shares valued at approximately $8.30 million. This move is part of a broader trend, as institutional investors now collectively own 97.42% of Soleno's stock, with other major firms like Vanguard Group and State Street also boosting their positions. Soleno Therapeutics, specializing in therapies for rare and orphan diseases, currently trades at $38.61 with a "Moderate Buy" analyst rating and a consensus price target of $110.62.
A Look At Soleno Therapeutics (SLNO) Valuation After Analyst Upgrades On VYKAT XR And Prader Willi Program
Soleno Therapeutics (SLNO) is gaining attention due to strong early sales of VYKAT XR and developments in its Prader Willi Syndrome program, leading to analyst upgrades. Despite recent short-term share price fluctuations, long-term holders have seen significant gains. While the company is widely considered undervalued with a fair value narrative suggesting $113.54, its current Price-to-Sales ratio of 21x is higher than industry averages, signaling potential valuation risk.
Soleno Therapeutics (SLNO) Expected to Announce Quarterly Earnings on Wednesday
Soleno Therapeutics (NASDAQ:SLNO) is expected to release its Q4 2025 earnings after market close on Wednesday, February 25, 2026, with analysts forecasting an EPS of $0.59 and revenue of $88.547 million. The company holds a "Moderate Buy" consensus rating with a price target of $110.62. Institutional investors own approximately 97.42% of the stock.
Commit To Purchase Soleno Therapeutics At $25, Earn 17.8% Annualized Using Options
Investors interested in Soleno Therapeutics (SLNO) can consider selling a September $25 strike put option to earn a 17.8% annualized return. This strategy offers a premium for committing to purchase shares at $25, providing a potential cost basis of $22.40 if the option is exercised, or simply the premium if the stock remains above $25. The article highlights the stock's trading history and volatility as factors to consider for this option strategy.
Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance
H.C. Wainwright and Wells Fargo analysts have both raised their price targets and reaffirmed Buy ratings for Soleno Therapeutics (SLNO), citing impressive sales figures and strong financial performance. Soleno Therapeutics, focused on rare disease therapies like Prader-Willi Syndrome, launched its leading product VYKAT XR in April 2025. Despite the positive outlook for SLNO, the article suggests that certain AI stocks may offer greater upside potential with less risk.
Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance
Soleno Therapeutics (SLNO) is gaining confidence from analysts due to its strong sales performance and promising pipeline. H.C. Wainwright raised its price target to $120, citing impressive sales figures and forecasting a 211% upside. Wells Fargo also increased its price target to $114, highlighting better-than-expected fourth-quarter earnings for VYKAT XR and deeming the shares undervalued given the company's robust cash flow.
Wellington Management Group LLP Increases Stake in Soleno Therap
Wellington Management Group LLP has increased its stake in Soleno Therapeutics Inc. by acquiring an additional 1,010,704 shares at $46.3 per share, bringing its total holdings to over 3.3 million shares. This move reflects Wellington's strategic interest in the biotechnology sector and Soleno's potential for developing novel therapeutics for rare diseases, despite the company's current financial challenges and negative stock performance since its IPO. The investment suggests confidence in Soleno's long-term growth prospects and innovative product offerings within the evolving biotechnology industry.
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Biotech Firm Surges with 200% Upside Potential
Soleno Therapeutics, a clinical-stage biopharmaceutical company with a market cap of $2 billion, is showing a potential upside of 200.55% according to analysts. Despite its stock trading at $37.24, near its 52-week low, 13 analysts rate it a "buy" with an average target price of $111.92, driven by its lead product in Phase III trials for Prader-Willi Syndrome. The company faces typical financial challenges of a developmental firm, with negative EPS and significant cash burn, making it a high-risk, high-reward opportunity dependent on clinical trial success and regulatory approval.
TimesSquare Capital Management LLC Has $25.52 Million Stake in Soleno Therapeutics, Inc. $SLNO
TimesSquare Capital Management LLC significantly increased its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 52.6% in the third quarter, now owning 377,566 shares valued at $25.52 million. This move, alongside other institutional investors like Goldman Sachs also raising their positions, contributes to a high institutional ownership of 97.42% for the company. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $110.62, indicating positive sentiment despite the stock trading around $37.24.
Soleno Therapeutics Updates PWS Launch, Reimbursement Trends and EU Review at Guggenheim Summit
Soleno Therapeutics provided updates at the Guggenheim Summit regarding its Prader-Willi syndrome (PWS) drug launch, projecting roughly 10% of the total addressable market (approximately 1,000 start forms) over 9-12 months. The company highlighted better-than-expected reimbursement across nearly 48 Medicaids and Medicare, with over 600 prescribers and European regulatory progress anticipating Day 180 questions for an EU4+UK patient pool of around 9,500. Soleno plans to transition from reporting start-form metrics to revenue and active patients after Q1, noting that real-world safety data aligns with clinical experience and general discontinuation rates are between 15-20%.
Soleno Therapeutics stock hits 52-week low at 37.95 USD By Investing.com
Soleno Therapeutics (SLNO) stock hit a 52-week low of $37.95, representing a significant decline of over 25% in the past year and more than 50% in the last six months. Despite this, analysts maintain an optimistic outlook with a "strong buy" consensus and price targets ranging from $60 to $145, expecting profitability this year. The company recently reported strong preliminary Q4 2025 revenues, surpassing expectations, though some analysts adjusted price targets while generally maintaining positive ratings due to robust financial results and strong market penetration for its Prader-Willi Syndrome treatment.
Soleno Therapeutics stock hits 52-week low at 37.95 USD By Investing.com
Soleno Therapeutics Inc. (SLNO) recently hit a 52-week low of $37.95, representing a significant decline over the past year despite being considered undervalued by InvestingPro. While the stock has faced volatility with a high beta of -3.18, analysts remain optimistic with a strong buy consensus and positive price targets. The company reported strong preliminary Q4 2025 revenue and full-year projections that exceeded expectations, with varying analyst price target adjustments from firms like Wolfe Research, H.C. Wainwright, Cantor Fitzgerald, Baird, and Stifel.
SLNO: Strong market uptake, stable safety, and robust reimbursement support ongoing growth
Soleno Therapeutics (SLNO) is demonstrating strong market uptake with 10% penetration, favorable reimbursement, and stable discontinuation rates. The company's revenue growth is fueled by an increasing patient base, and future strategies include international expansion and new indications. This information is based on an AI-generated summary of their Guggenheim Securities Biotech Summit audio transcript.
Soleno Therapeutics stock hits 52-week low at 37.95 USD
Soleno Therapeutics (SLNO) stock hit a 52-week low of $37.95, reflecting a 25.39% decline in stock value over the past year and a 51.96% drop over six months. Despite this, InvestingPro data suggests the stock is undervalued, and analysts maintain a strong buy consensus with price targets up to $145, predicting profitability this year. The company also reported strong preliminary Q4 2025 revenue, exceeding expectations.
Rare disease biotech Soleno sets Feb. 25 call on 2025 results
Soleno Therapeutics (NASDAQ: SLNO) will report its fourth-quarter and full-year 2025 financial results on February 25, 2026, after market close. The company will host a conference call and webcast at 4:30 PM ET to discuss the results and provide an update on business operations. Investors are anticipated to focus on how final audited figures compare to preliminary results, management's commercial outlook, and any updated operational milestones.
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET
Soleno Therapeutics will report its fourth quarter and full-year 2025 financial results and operational highlights after market close on Wednesday, February 25, 2026. The company will host a conference call and webcast at 4:30 PM ET to discuss the results and provide a business operations update. Soleno Therapeutics is a biopharmaceutical company focused on developing novel therapeutics for rare diseases, with their first commercial product being VYKAT™ XR for Prader-Willi syndrome.
Soleno Therapeutics to Report Fourth Quarter and Full-Year
Soleno Therapeutics announced it will report its fourth quarter and full-year 2025 financial results and operational highlights on February 25, 2026, after market close. The company will host a conference call and webcast at 4:30 PM ET to discuss these results and provide a business update. Soleno Therapeutics focuses on developing novel therapeutics for rare diseases, with their first commercial product being VYKAT™ XR for hyperphagia in Prader-Willi syndrome.
Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Soleno Therapeutics (SLNO) shows signs of a potential trend reversal after a recent 10% stock loss, indicated by the formation of a hammer chart pattern. This technical signal suggests subsiding selling pressure and emerging buying interest. Furthermore, bullish fundamental indicators, such as a 3% increase in consensus EPS estimates over the last 30 days and a Zacks Rank #1 (Strong Buy), reinforce the likelihood of an upward trend.
Why a biotech is drawing attention to a rare disease at the Super Bowl
Soleno Therapeutics is using the Super Bowl LX program, rather than TV ads, to raise awareness for Prader-Willi syndrome (PWS), a rare genetic disease causing insatiable hunger. The ad, co-branded with the Prader-Willi Syndrome Association, focuses on educating the public about PWS and its hallmark symptom, hyperphagia, to help affected families feel less isolated. The company believes print offers a more thoughtful engagement opportunity, reaching an estimated 1 million readers through the program and millions more via the digital version on NFL.com.
What Soleno Therapeutics (SLNO)'s VYKAT XR Momentum and 2025 Outlook Could Mean For Shareholders
Soleno Therapeutics (SLNO) is highlighting 2025 as a transformational year for its drug VYKAT XR, with strong preliminary revenue and upcoming financial results. The company is transitioning from a clinical-stage to a commercial entity, focusing on VYKAT XR's launch, and preparing for investor conferences to showcase its rare disease portfolio. While there is enthusiasm, the company faces risks including high sales multiples, share price volatility, and unproven earnings sustainability, alongside governance and valuation concerns.
A Look At Soleno Therapeutics (SLNO) Valuation After VYKAT XR Launch And Upcoming 2025 Business Updates
Soleno Therapeutics (SLNO) is gaining investor attention after framing 2025 as a transformative year and highlighting early success for its drug VYKAT XR. Despite recent share price declines, analysts project a significantly higher fair value, suggesting major undervaluation. Both narrative-based and DCF models indicate substantial upside, with a first-mover advantage for their FDA-approved therapy for Prader-Willi Syndrome.
A Look At Soleno Therapeutics (SLNO) Valuation After VYKAT XR Launch And Upcoming 2025 Business Updates
Soleno Therapeutics (SLNO) is gaining investor interest due to its "transformational" 2025 outlook, strong early VYKAT XR traction, and upcoming financial results. Despite recent stock declines, two valuation models suggest significant undervaluation: a narrative-based model points to a fair value of $143.71, while a DCF model indicates an even higher fair value of $436.04 compared to the current $42.32 share price, highlighting potential for future growth.
Soleno Therapeutics stock jumps nearly 9% today — what SLNO traders are watching next
Soleno Therapeutics (SLNO) shares surged nearly 9% after its drug VYKAT XR, approved for Prader-Willi syndrome, showed strong preliminary 2025 net revenue and ended the year profitably with $500 million in cash. The company's future performance hinges on VYKAT XR's launch momentum, while investors are closely watching upcoming financial reports and investor conference appearances. A recent peer-reviewed study reinforcing the drug's efficacy further solidified investor confidence.
Universal Beteiligungs und Servicegesellschaft mbH Sells 32,627 Shares of Soleno Therapeutics, Inc. $SLNO
Universal Beteiligungs und Servicegesellschaft mbH has significantly reduced its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by selling 32,627 shares, cutting its holdings by 74% to 11,441 shares. Despite this sell-off, institutional ownership remains high at about 97.42%, and analysts largely maintain a "Buy" rating with an average price target of $110.62. Soleno Therapeutics recently reported strong quarterly earnings, beating revenue and EPS estimates, yet its stock trades near its 52-week low.
Soleno Therapeutics Shares Dip Following $200 Million Stock Offering Pricing
Soleno Therapeutics' shares experienced a price drop after the company announced the pricing of a $200 million public stock offering. The offering includes 4 million shares of common stock and an additional 1.2 million pre-funded warrants, priced at $40.00 and $39.99 per share/warrant respectively. The biotech sector, represented by the Nasdaq Biotechnology Index, saw a slight decline of 0.28% on the same day.
Soleno Therapeutics stock hits 52-week low at 39.42 USD
Soleno Therapeutics (SLNO) stock hit a 52-week low of $39.42, reflecting a 21.12% decline over the past year and a 52.22% drop in the last six months. Despite this, InvestingPro data suggests the stock is undervalued with a "strong buy" analyst consensus and a forecasted EPS of $6.24 for FY2025, indicating expected profitability this year. The company recently reported Q4 2025 revenue for its Vykat treatment that exceeded expectations, though analyst price targets have varied.
Three health-care investor events lined up for Soleno Therapeutics
Soleno Therapeutics (NASDAQ: SLNO) is scheduled to participate in three investor conferences between February and March 2026: Guggenheim Emerging Outlook: Biotech Summit, Oppenheimer 36th Annual Healthcare Life Sciences Conference, and TD Cowen 46th Annual Health Care Conference. The company will deliver presentations, including fireside chats and a company presentation, with webcasts and replays available in the investors section of its website. These events follow recent positive company milestones, such as preliminary 2025 revenue results for VYKAT XR and a significant share repurchase.
Soleno Therapeutics to Participate in Upcoming Conferences
Soleno Therapeutics announced its participation in three investor conferences in February and March 2026: the Guggenheim Emerging Outlook: Biotech Summit, Oppenheimer 36th Annual Healthcare Life Sciences Conference, and TD Cowen 46th Annual Health Care Conference. The company will present its developments, including VYKAT™ XR for Prader-Willi syndrome, which received FDA approval in March 2025. Webcasts for two of the events will be available on Soleno's website.
Soleno Therapeutics to Participate in Upcoming Conferences
Soleno Therapeutics, Inc., a biopharmaceutical company specializing in rare diseases, announced its participation in several investor conferences in February and March 2026. The company will present at the Guggenheim Emerging Outlook: Biotech Summit, Oppenheimer 36th Annual Healthcare Life Sciences Conference, and the TD Cowen 46th Annual Health Care Conference. Soleno's first commercial product, VYKAT™ XR, an FDA-approved treatment for hyperphagia in Prader-Willi syndrome, was approved in March 2025.
Soleno Therapeutics to Participate in Upcoming Conferences
Soleno Therapeutics announced its participation in three upcoming investor conferences in February and March 2026. The company will present at the Guggenheim Emerging Outlook: Biotech Summit, Oppenheimer 36th Annual Healthcare Life Sciences Conference, and TD Cowen 46th Annual Health Care Conference, providing updates on its novel therapeutics for rare diseases, including VYKAT™ XR for Prader-Willi syndrome.
Solena Therapeutics (SLNO) Stock Under Pressure But Upside is Huge
Solena Therapeutics (SLNO) stock is currently under pressure despite multiple bullish analyst ratings and price target increases. The company, a clinical-stage biopharmaceutical firm focusing on rare diseases, saw its fourth-quarter sales for Vykat XR exceed expectations, yet new patient start forms are impacting stock performance. While analysts see significant upside, Wolfe Research cut its price target, indicating concerns about market valuation reflecting a bear-case scenario for product uptake.
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts
Soleno Therapeutics (NASDAQ:SLNO) has received an average "Buy" recommendation from fifteen analysts, with a consensus 12-month price target of $110.62. Institutional investors significantly increased their stakes in Q3, now owning 97.42% of the company. Despite beating Q3 earnings expectations with an EPS of $0.47 against an expected $0.08, the stock trades around $42.36, substantially below its 12-month high of $90.32.
Emerald Mutual Fund Advisers Trust Reduces Position in Soleno Therapeutics, Inc. $SLNO
Emerald Mutual Fund Advisers Trust reduced its stake in Soleno Therapeutics by 6.3%, now owning 379,900 shares valued at $25.7 million. Despite the reduction, institutional investors collectively hold 97.42% of the company's stock. Soleno Therapeutics recently surpassed quarterly earnings expectations, and several analysts have raised their price targets and reiterated "Buy" ratings, though a "Sell" rating still exists from a minority firm.
Is Soleno Therapeutics, Inc. (NASDAQ:SLNO) The Best Under $50 Stock to Buy Now?
Soleno Therapeutics (NASDAQ:SLNO) has received increased price targets from H.C. Wainwright and Wells Fargo following strong preliminary 4Q25 and full-year 2025 financial results for its VYKAT XR offering. The company's net revenue surpassed estimates, with Q4 2025 net revenue anticipated to be significantly higher than analyst guidance. Analysts see potential for further growth and believe the stock is trading at a discount given its free cash flow profile.
Soleno Therapeutics Inc. (SLNO): Analysts See Major Upside
Soleno Therapeutics Inc. (SLNO) is gaining significant attention from analysts due to its lead product, Vykat, for Prader-Willi Syndrome. Cantor Fitzgerald reiterated an Overweight rating with a $123 price target, citing the company's 12.5% market share. Baird also maintained an Outperform rating, lowering its target slightly to $107 but still indicating substantial upside from its current trading price.
Soleno Therapeutics Inc. (SLNO): Analysts See Major Upside
Analysts are largely optimistic about Soleno Therapeutics Inc. (SLNO), with Cantor Fitzgerald reiterating an Overweight rating and a $123 price target due to strong market penetration of its Prader-Willi Syndrome treatment, Vykat. Despite Baird lowering its price target to $107, it maintained an Outperform rating, highlighting significant upside from the current share price of about $41. The company's lead product, VYKAT XR, an FDA-approved therapy for hyperphagia in PWS patients, is expected to drive substantial revenue growth.
Soleno Therapeutics (SLNO) Valuation Checked After New Q4 2025 Revenue Guidance
Soleno Therapeutics (SLNO) released preliminary Q4 2025 revenue guidance of US$90M-US$92M, causing its share price to decline by 31.57% over three months, despite substantial long-term gains. The company's Price-to-Sales ratio of 23.7x suggests it is overvalued compared to its peers and the industry average, likely due to investor expectations for future pipeline success. However, a Discounted Cash Flow model indicates the shares might be significantly undervalued, trading about 90.2% below an estimated future cash flow value, highlighting differing valuation perspectives.
Soleno Therapeutics (SLNO) Valuation Checked After New Q4 2025 Revenue Guidance
Soleno Therapeutics (SLNO) recently released Q4 2025 revenue guidance of US$90-US$92 million, leading to a valuation discussion. The stock's Price-to-Sales ratio of 23.7x is high compared to peers, suggesting it's overvalued by this metric, yet a Discounted Cash Flow (DCF) model indicates it might be significantly undervalued by approximately 90.2%. This discrepancy highlights the stock's sensitivity to future revenue assumptions for its drug, Diazoxide Choline.
Emerald Advisers LLC Trims Position in Soleno Therapeutics, Inc. $SLNO
Emerald Advisers LLC reduced its stake in Soleno Therapeutics (NASDAQ:SLNO) by 6.7% in the third quarter, selling 45,152 shares and now holding 627,756 shares valued at $42.44 million. Despite the institutional trimming, analysts maintain a "Buy" consensus with an average price target of $110.62, while the company recently beat earnings and revenue expectations. Soleno Therapeutics, focusing on rare and orphan diseases, trades at $43.56 with institutional investors owning 97.42% of its stock.
Soleno Therapeutics, Inc. (SLNO) Stock Analysis: Exploring A 160% Potential Upside
Soleno Therapeutics, Inc. (SLNO) is a biotechnology company with a market cap of $2.28 billion, showing a potential upside of 160.21% according to financial analysts who have set an average target price of $110.54. The company focuses on rare diseases, with its lead candidate in Phase III trials for Prader-Willi Syndrome. Despite current technical bearish indicators and negative earnings common for pre-revenue biotech firms, the company is seen as a compelling high-risk, long-term growth opportunity due to its innovative approach and strong analyst confidence.
VYKAT XR FDA Nod and Phase 3 Data Could Be A Game Changer For Soleno Therapeutics (SLNO)
Soleno Therapeutics' VYKAT XR has received FDA approval for Prader-Willi syndrome, supported by strong Phase 3 data, positioning the company to transition from development to commercial execution. Despite positive early revenue guidance of US$90M-US$92M for Q4 2025, market sentiment indicates some skepticism about revenue repeatability and peak demand. The company faces risks related to sustaining prescription growth and justifying its valuation while operating unprofitably.
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman
Hagens Berman is investigating Soleno Therapeutics (NASDAQ: SLNO) after its shares dropped 28% following disappointing news regarding its drug VYKAT™ XR for Prader-Willi syndrome. The investigation focuses on Soleno's statements about the drug's safety and commercial prospects, especially after a short seller report highlighted concerns about adverse events, Soleno's financial viability, and data integrity. Investors who suffered significant losses are urged to contact Hagens Berman.
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman
Hagens Berman is investigating Soleno Therapeutics (SLNO) after its shares plummeted by 28% following disappointing news regarding its drug VYKAT™ XR. The firm questions Soleno's previous assurances about the drug's commercial prospects, especially after a short seller's report highlighted concerns about patient hospitalizations, the drug's efficacy compared to older treatments, and potential data integrity issues in trials. Investors who suffered significant losses are urged to contact Hagens Berman.
Q4 EPS Estimate for Soleno Therapeutics Increased by Analyst
Lifesci Capital has increased its Q4 2025 EPS estimate for Soleno Therapeutics to $0.59 and projects FY2026 EPS of $3.42, a significant increase from previous forecasts. This upgrade follows Soleno Therapeutics' recent strong earnings report, where the company surpassed analyst expectations for both EPS and revenue. Analyst sentiment for Soleno Therapeutics remains largely positive, with an average "Buy" rating and a consensus price target of $109.23.
Soleno Therapeutics (SLNO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Soleno Therapeutics (SLNO) has recently experienced a 10% stock price drop but shows signs of a potential trend reversal due to a hammer chart pattern formation. This technical indicator, coupled with strong fundamental support from an upward trend in earnings estimate revisions and a Zacks Rank #1 (Strong Buy), suggests that the stock may find a bottom soon. Analysts are in agreement that the company is expected to report improved earnings, making a bullish case for SLNO.
Relative Strength Alert For Soleno Therapeutics
Soleno Therapeutics Inc (SLNO) shares have entered oversold territory with an RSI reading of 28.7, indicating potential for a buying opportunity. The stock's current price of $39.91 is near its 52-week low of $39.43, contrasting with a high of $90.3199. This technical signal suggests that recent heavy selling might be exhausting, making it an interesting point for bullish investors to consider.
A Look At Soleno Therapeutics (SLNO) Valuation After Profitable Q4 2025 And VYKAT XR Adoption
Soleno Therapeutics (SLNO) reported profitable Q4 2025 results and positive cash flow, driven by VYKAT XR adoption. Despite recent profitability and analyst targets, its stock price has been under short-term pressure, though long-term holders have seen significant gains. The article examines Soleno's valuation, finding it appears overvalued based on a P/S ratio of 22.6x compared to industry averages, but potentially undervalued according to a Discounted Cash Flow (DCF) model which suggests a fair value significantly higher than its current share price.
Baird lowers Soleno Therapeutics stock price target to $107 on new starts trajectory
Baird has lowered its price target for Soleno Therapeutics (NASDAQ:SLNO) to $107 from $121, while maintaining an Outperform rating. This adjustment comes despite Soleno's preliminary fourth-quarter 2025 sales for Vykat exceeding estimates, due to lower-than-expected new patient start forms. The firm believes market sentiment is "overly negative" and anticipates future sales growth, while other analysts like Wolfe Research also adjusted targets.
